Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Subscribe To Our Newsletter & Stay Updated
